Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

Also called NCT02542631

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 278 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02542631
  • EudraCT 2015-003761-28
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, France, Germany, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02542631. Randomized; no masking; primary purpose treatment. Start 2015-08-01 (actual); primary completion 2017-08-31 (actual). Results posted on 2018-11-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients
Condition
Diabetes Mellitus, Type 2
Intervention (Device)
Bolus Insulin Patch (Calibra Finesse)
Intervention (Device)
Insulin Pen (Novo-Nordisk FlexPen®)
Lead sponsor
Calibra Medical, Inc. (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02542631
Content hash
c9697d38aedfa9cd17dd78300b85dcade920aa64d9d99080a579eae0308506e4